Bayer will not appeal a $20.5 million Roundup verdict—the first Roundup verdict in the nation—to the U.S. Supreme Court, the company announced [March 19].
The decision will end the litigation brought by Dewayne Johnson against Bayer’s Monsanto over claims its Roundup pesticide caused his non-Hodgkin lymphoma. A California jury awarded Johnson a $289 million verdict in 2018, reduced to $20.5 million on appeal.
Bayer said the case is not the best fit for Supreme Court review because the underlying opinion was issued by an intermediate-level state court, California’s First District Court of Appeal, and the portion dealing with whether federal law preempts the state’s duty-to-warn theory is unpublished, and “thus will have no bearing on any case besides Johnson[‘s].”
In October, the U.S. Court of Appeals for the Ninth Circuit heard arguments on whether to reverse an $80 million Roundup verdict based on federal preemption in a case brought by Edwin Hardeman.
In contrast, the company said, “the Hardeman case, regardless of its outcome in the U.S. Court of Appeals, is a better candidate for Supreme Court review because the intermediate federal court is expected to publish a decision addressing the most significant federal questions at issue in the Roundup litigation, including preemption and the admissibility of expert evidence.”